8.77
0.04 (0.52%)
| Penutupan Terdahulu | 8.72 |
| Jumlah Dagangan | 729,296 |
| Harga / Jualan (P/S) | 3.65 |
| Harga / Buku (P/B) | 2.49 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.01 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.02% |
| Nisbah Semasa (MRQ) | 10.89 |
| Aliran Tunai Operasi (OCF TTM) | -106.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.07 M |
| Pulangan Atas Aset (ROA TTM) | -30.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Solid Biosciences Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.83 |
|
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.52% |
| % Dimiliki oleh Institusi | 102.40% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2026 | 9,808,819 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |